Alicia Danforth
Clinical Psychologist and Clinical Trial Researcher
Data updated
Research Footprint
Alicia Danforth appears in 5 tracked papers (2011–2020), most studied alongside MDMA and Psilocybin, across Anxiety Disorders, Autism Spectrum Disorder (ASD) and Safety & Risk Management.
Most-cited paper: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer (1209 citations).
Frequent co-authors: Charles Grob, Berra Yazar-Klosinski and Adam Halberstadt.
Background & Research
Alicia Danforth is a clinical psychologist and psychedelic researcher whose work has focused on autistic adults, neurodiversity, and therapeutic applications of MDMA-assisted psychotherapy. She has served as an investigator on studies of MDMA-assisted therapy for social anxiety in autistic adults and has also been involved in psilocybin research in cancer and palliative-care contexts. Her website describes her as maintaining a dual career in clinical practice and clinical trial research.
Key Impact
She is a notable clinical researcher in psychedelic-assisted therapy, especially for autistic adults, and co-authored early studies of MDMA-assisted psychotherapy and psilocybin-related work in psychiatric and palliative care settings.
Collaboration Network
11 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Alicia Danforth is associated with.
The Lundquist Institute at Harbor-UCLA
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is an independent, nonprofit biomedical research institute located on the Harbor‑UCLA campus in Torrance, California. It conducts translational and clinical research across areas such as cancer, infectious disease, and genomics and is affiliated with UCLA’s David Geffen School of Medicine.
View stakeholder →MAPS
nonprofitMAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.
View stakeholder →